Crawford M H
Circulation. 1987 Jun;75(6 Pt 2):V122-7.
Despite the proven effectiveness of calcium-channel and beta-blockers as monotherapy in patients with chronic stable angina pectoris, some patients remain symptomatic. Such patients have been shown to benefit from the application of combined treatment with beta-blockers and nitrates or, more recently, beta-blockers plus calcium-channel blockers. There have been few studies evaluating the long-term effectiveness of the combination of calcium blockers and nitrates, but available evidence suggests that symptoms of excessive vasodilation such as orthostatic hypotension may limit the usefulness of this approach. Recently, the additional benefit of adding a calcium blocker to therapy of patients with chronic stable angina who remain symptomatic on beta-blockers and nitrates has been demonstrated. Side effects related to vasodilation were the major limiting feature of this triple therapy. Thus, a triple therapy regimen may be of value in selected patients who do not respond to the combination of beta-blockers and nitrates or beta-blockers plus calcium blockers. However, caution must be exercised in patients with reduced left ventricular function and conduction system disease, since such patients have been excluded from the reported studies.
尽管钙通道阻滞剂和β受体阻滞剂作为慢性稳定型心绞痛患者的单一疗法已被证明有效,但仍有一些患者有症状。已表明此类患者可从β受体阻滞剂与硝酸盐联合治疗中获益,或者最近从β受体阻滞剂加钙通道阻滞剂联合治疗中获益。评估钙通道阻滞剂与硝酸盐联合治疗长期有效性的研究很少,但现有证据表明,诸如体位性低血压等过度血管舒张症状可能会限制这种方法的实用性。最近,已证明在使用β受体阻滞剂和硝酸盐后仍有症状的慢性稳定型心绞痛患者的治疗中添加钙通道阻滞剂有额外益处。与血管舒张相关的副作用是这种三联疗法的主要限制因素。因此,三联疗法方案对于对β受体阻滞剂与硝酸盐联合治疗或β受体阻滞剂加钙通道阻滞剂联合治疗无反应的特定患者可能有价值。然而,对于左心室功能减退和传导系统疾病患者必须谨慎,因为此类患者被排除在已报道的研究之外。